Atlas Trials

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

Clinical trial NCT01261767 · TERMINATED

Trial details

NCT number
NCT01261767
Sponsor
Novo Nordisk A/S
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
InflammationPsoriasis
Start date
2008-04-01
Primary completion
2011-01-01
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.